Disease relevance of Heart-Lung Transplantation

• End-stage heart failure with pulmonary hypertension: levosimendan to evaluate for heart transplantation alone versus combined heart-lung transplantation [1].
• METHODS: We prospectively studied ET-1 concentration in lung specimens from 6 control subjects and 13 patients with severe PH referred for lung or heart-lung transplantation (6 patients had primary PH and 7 PH secondary to congenital heart defect) [2].
• BACKGROUND: Twenty-one to 63% of patients with cystic fibrosis (CF) accepted for lung and heart-lung transplantation die on the waiting list [3].
• Steroid-responsive bronchiolitis after human heart-lung transplantation [4].
• Heart-lung transplantation is performed for Eisenmenger's syndrome and for primary pulmonary hypertension with severe right ventricular failure [5].

High impact information on Heart-Lung Transplantation

• Detection of lung rejection with indium-111-labeled lymphocytes in heterotopic rat heart-lung transplantation [6].
• The persistent decrease in platelet storage of serotonin after heart-lung transplantation suggests that this platelet abnormality is not secondary to PPH [7].
• After heart-lung transplantation, platelet serotonin concentrations remained decreased and plasma levels remained increased [7].
• Responders and non-responders were followed prospectively and the primary endpoint of the study was cardiopulmonary death, the secondary endpoint the combination of death, need for treatment with prostacyclin or heart-lung transplantation [8].
• CONCLUSIONS: These results suggest that potential renoprotective strategies following lung or heart-lung transplantation include avoidance of peri-transplant renal injury, diligent blood pressure control, and preferential use of tacrolimus over cyclosporine [9].

Chemical compound and disease context of Heart-Lung Transplantation

• Combined heart-lung transplantation with cyclosporine is reported in a 26-year-old patient who presented with end-stage pulmonary lymphangioleiomyomatosis [10].
• Lung and heart-lung transplantation for end-stage lung disease. The Bordeaux Lung and Heart-Lung Transplant Group [11].
• Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension [12].
• The role of allopurinol in the prevention of ischemia-reperfusion injury was assessed in a model of heart-lung transplantation [13].
• Comparison of new iron chelating agents in the prevention of ischemia/reperfusion injury: a swine model of heart-lung transplantation [14].

Anatomical context of Heart-Lung Transplantation

• Adenine nucleotide catabolism in human myocardium during heart and heart-lung transplantation [15].

Associations of Heart-Lung Transplantation with chemical compounds

• This result provides an objectively defined therapeutic threshold for targeting early cyclosporine concentrations following heart-lung transplantation [16].
• Correlation of red cell antioxidant status and heart-lung function in swine pretreated with allopurinol (a model of heart-lung transplantation) [17].
• Bronchial reactivity to methacholine after combined heart-lung transplantation [18].
• In the present study, the effects of allopurinol pretreatment in a model of heart-lung transplantation were examined in swine, a species devoid of myocardial xanthine oxidase activity [17].
• The long-term use of low-dose prednisone before heart-lung transplantation does not preclude normal tracheal healing [19].

Gene context of Heart-Lung Transplantation

• In 20 consecutive patients who underwent HTx or heart-lung transplantation (HLTx), plasma levels of tumor necrosis factor alpha, IL-6, IL-8, and anti-inflammatory cytokine IL-10 were measured before heparin administration, at aortic cross-clamping and declamping, and 0.5, 1, 1.5, 2, 4, 12, and 24 hours after aortic declamping [20].
• Sequential use of G-CSF and GM-CSF after heart-lung transplantation [21].
• The finding that the preponderant cells expressed the CD8 (putative cytotoxic/suppressor) marker lends support to the notion that chronic rejection is at least one mechanism for the development of bronchiolotis obliterans following heart-lung transplantation [22].
• Successful use of alternate waste nitrogen agents and hemodialysis in a patient with hyperammonemic coma after heart-lung transplantation [23].
• Recurrent fatal pulmonary alveolar proteinosis after heart-lung transplantation in a child with lysinuric protein intolerance [24].

Analytical, diagnostic and therapeutic context of Heart-Lung Transplantation

• The lungs from 16 cases of plexogenic pulmonary arteriopathy obtained at heart-lung transplantation, half of which had primary pulmonary hypertension, were examined by electron microscopy [25].
• XO activity was measured in healthy human lung tissue, and XO protein and the adenine nucleotide catabolic products hypoxanthine, xanthine and uric acid were analysed in the plasma samples collected during human heart-lung transplantation (n=4), double lung transplantation (n=2), and single lung transplantation (n=1) [26].
• BACKGROUND: The operation of choice for primary pulmonary hypertension remains controversial, as heart-lung transplantation, single-lung transplantation, and double-lung transplantation have all been advocated [27].
• Bilateral lung transplantation, ventricular septal defect closure and pulmonary homograft reconstruction of the right ventricular outflow tract to the transplanted lungs was performed in three children by means of a new technique that avoids the need for combined heart-lung transplantation [28].
• Failure of whole blood cyclosporine levels to provide a reliable measure of immunosuppression in clinical heart and heart/lung transplantation [29].

References